Shire PLC (ADR)  

(Public, NASDAQ:SHPG)   Watch this stock  
Find more results for Shire US, Inc
147.36
+0.58 (0.40%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 145.98 - 147.54
52 week 86.01 - 172.27
Open 147.32
Vol / Avg. 255,429.00/563,897.00
Mkt cap 29.35B
P/E 20.29
Div/yield 0.51/0.41
EPS 7.26
Shares 199.17M
Beta 0.75
Inst. own 16%
May 1, 2014
Q1 2014 Shire Plc Earnings Release Add to calendar
Apr 29, 2014
Shire Plc Annual Shareholder Meeting Add to calendar
Mar 10, 2014
Shire Plc at EBD BIO-Europe Spring
Mar 4, 2014
Shire Plc at Cowen Health Care Conference
Mar 4, 2014
Shire Plc at Credit Suisse Healthcare Conference
Feb 13, 2014
Full Year 2013 Shire Plc Earnings Conference Call
Feb 13, 2014
Full Year 2013 Shire Plc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 64.63% 28.69%
Operating margin 73.08% 35.13%
EBITD margin - 40.09%
Return on average assets 39.13% 18.10%
Return on average equity 68.86% 30.94%
Employees 5,338 -
CDP Score - 83 C

Address

Citywest Business Campus 5 Riverwalk, Dublin 24
DUBLIN, ENG
Ireland
+353-1-4297700 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. On January 31, 2012, the United States Food and Drug Administration approved VYVANSE for the maintenance treatment of ADHD in adults. In March 2013, it announced the acquisition Of Premacure AB. In January 2014, Shire Plc sold its DERMAGRAFT assets to Organogenesis Inc. In January 2014, Shire Plc acquired 79.5% interest in ViroPharma Inc.

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
James Bowling Interim Chief Financial Officer
Age: 45
Bio & Compensation  - Reuters
Jeffrey M. Jonas M.D. President - Regenerative Medicine
Age: 59
Bio & Compensation  - Reuters
Tatjana May General Counsel, Company Secretary
Age: 47
Bio & Compensation  - Reuters
Matthew W. Emmens Non-Executive Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
David J. Kappler Senior Independent Non-Executive Deputy Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Dominic Blakemore Non-Executive Director
Age: 44
Bio & Compensation  - Reuters
William Burns Non-Executive Independent Director
Age: 65
Bio & Compensation  - Reuters
Steven H. Gillis Ph.D. Non-Executive Independent Director
Bio & Compensation  - Reuters